0001728215-18-000001.txt : 20180122 0001728215-18-000001.hdr.sgml : 20180122 20180122165345 ACCESSION NUMBER: 0001728215-18-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180122 DATE AS OF CHANGE: 20180122 EFFECTIVENESS DATE: 20180122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MPX Bioceutical Corp CENTRAL INDEX KEY: 0001728215 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-303844 FILM NUMBER: 18540361 BUSINESS ADDRESS: STREET 1: 5255 YONGE STREET, SUITE 701 CITY: TORONTO STATE: A6 ZIP: M2N 6P4 BUSINESS PHONE: (416) 840-3725 MAIL ADDRESS: STREET 1: 5255 YONGE STREET, SUITE 701 CITY: TORONTO STATE: A6 ZIP: M2N 6P4 D 1 primary_doc.xml X0708 D LIVE 0001728215 MPX Bioceutical Corp 5255 YONGE STREET, SUITE 701 TORONTO A6 ONTARIO, CANADA M2N 6P4 (416) 840-3725 ONTARIO, CANADA The Canadian Bioceutical Corporation Allegiance Equity Corporation None Corporation true W. Scott Boyes 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Executive Officer Director Jeremy S. Budd 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Executive Officer David McLaren 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Executive Officer Elizabeth M. Stavola 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Executive Officer Director Robert R. Galvin 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Director Andrew R. Ryan 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Director Richard S. Segerblom 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Director Randall G. Stafford 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Director Miles D. Thompson 5255 Yonge Street, Suite 701 Toronto A6 ONTARIO, CANADA M2N 6P4 Director Pharmaceuticals $1,000,001 - $5,000,000 06b false 2017-01-19 false true true 0 2480000 2480000 0 false 20 0 0 0 true A portion of the proceeds of the offering was designated for general working capital purposes and thus was available for payments to officers and directors in the ordinary course, but no amount was specifically earmarked for such payments. false MPX Bioceutical Corp /s/ Jeremy S. Budd Jeremy S. Budd VP, General Counsel and Corporate Secretary 2018-01-22